NeuroSense targets December 2026 Canadian filing for PrimeC ALS therapy

Sep 25, 2026 20:30 (30d ago)

Verifying

NeuroSense targets a December 2026 Canadian New Drug Submission for PrimeC in ALS.
65% lower death risk was reported for participants continuously treated with PrimeC.
NeuroSense completed Health Canada's Pre-New Drug Submission process before the planned filing.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.